Refractory precursor T-lymphoblastic lymphoma/leukemia

This early-stage trial is testing an experimental cell therapy called HY035 in people with CD7-positive blood cancers that have returned or not responded to standard treatment. The goal is to see if the therapy is safe and can help achieve remission. Participants receive a single…

This trial tests an experimental drug called OBI-3424 in people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has returned or not responded to treatment. The drug is designed to become active mainly inside cancer cells that produce a specific enzy…

This early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…

This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This study tests a new treatment for adults with a type of leukemia (T-ALL) that has come back or not responded to standard therapy. The treatment combines an immunotherapy drug (PD-1 inhibitor) with a targeted drug (venetoclax) and chemotherapy. The goal is to see if this combin…

This trial is testing whether adding two targeted drugs, venetoclax and navitoclax, to standard chemotherapy can help children and young adults with acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. The study has two phases: first, finding the b…